Literature DB >> 7969240

Passive transfer of seronegative myasthenia gravis to mice.

J Burges1, A Vincent, P C Molenaar, J Newsom-Davis, C Peers, D Wray.   

Abstract

Muscle weakness in myasthenia gravis is due to autoantibody-induced loss of functional acetylcholine receptors (AChR). About 15% of myasthenia gravis patients, however, do not have detectable anti-AChR antibodies. To investigate the effect of their plasma immunoglobulins on neuromuscular transmission, mice were injected with plasma (and in some cases purified immunoglobulin G (IgG)) from 7 "seronegative" myasthenia gravis (SMG) patients, and neuromuscular transmission parameters were examined. When injected for 15 days, all patients' plasma caused reductions in miniature endplate potential amplitudes, while endplate potential quantal content was significantly reduced by plasma from 4 of the 7 patients. There were no changes in ACh-induced depolarization or single channel properties, and 125I-alpha-bungarotoxin binding studies showed no effect on AChR number, except in 1 case. Purified IgG injected for 3 days had similar effects to plasma injected for 15 days. Our findings confirm that SMG is autoantibody mediated and that there are pathogenic IgG antibodies. SMG appears to be a heterogeneous disorder and the target(s) for the antibodies may be diverse.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7969240     DOI: 10.1002/mus.880171208

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  9 in total

1.  Autonomic "myasthenia": the case for an autoimmune pathogenesis.

Authors:  Daniel B Drachman
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

2.  Guidelines for pre-clinical assessment of the acetylcholine receptor--specific passive transfer myasthenia gravis model-Recommendations for methods and experimental designs.

Authors:  Linda L Kusner; Mario Losen; Angela Vincent; Jon Lindstrom; Socrates Tzartos; Konstantinos Lazaridis; Pilar Martinez-Martinez
Journal:  Exp Neurol       Date:  2015-03-03       Impact factor: 5.330

3.  Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice.

Authors:  R N Cole; N Ghazanfari; S T Ngo; O L Gervásio; S W Reddel; W D Phillips
Journal:  J Physiol       Date:  2010-07-05       Impact factor: 5.182

4.  The features of myasthenia gravis with autoantibodies to MuSK.

Authors:  D Lavrnic; M Losen; A Vujic; M De Baets; L J Hajdukovic; V Stojanovic; R Trikic; P Djukic; S Apostolski
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-08       Impact factor: 10.154

Review 5.  The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis.

Authors:  Inga Koneczny; Judith Cossins; Angela Vincent
Journal:  J Anat       Date:  2013-03-04       Impact factor: 2.610

Review 6.  The emerging diversity of neuromuscular junction disorders.

Authors:  J Newsom-Davis
Journal:  Acta Myol       Date:  2007-07

7.  Myasthenia gravis in a patient affected by glycogen storage disease type Ib: a further manifestation of an increased risk for autoimmune disorders?

Authors:  D Melis; F Balivo; R Della Casa; A Romano; R Taurisano; B Capaldo; G Riccardi; M R Monsurrò; G Parenti; G Andria
Journal:  J Inherit Metab Dis       Date:  2008-04-21       Impact factor: 4.982

8.  The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates.

Authors:  W Pascale ter Beek; Pilar Martínez-Martínez; Mario Losen; Marc H de Baets; Axel R Wintzen; Jan J G M Verschuuren; Erik H Niks; Sjoerd G van Duinen; Angela Vincent; Peter C Molenaar
Journal:  Am J Pathol       Date:  2009-09-10       Impact factor: 4.307

Review 9.  Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture.

Authors:  Inga Koneczny; Ruth Herbst
Journal:  Cells       Date:  2019-07-02       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.